Francisca Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francisca Castillo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Cecilia Bosdotter
25 shared publicationsDanai Lianoudaki
25 shared publications- Diana Spiegelberg
Department of Surgical Sciences, Uppsala University
25 shared publications - Dilraj Lama
Department of Microbiology, Tumor and Cell Biology, Biomedicum B7, Karolinska Institutet, Stockholm, Sweden
25 shared publications - Eduardo J. Villablanca
Karolinska Institutet and University Hospital
25 shared publications - Fredrik Wermeling
Department of Medicine, Division of Rheumatology, Karolinska Institutet, and Center for Molecular Medicine (CMM), Karolinska University Hospital, Stockholm, Sweden
25 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Navtemadlin treatment does not affect tumor infiltrating lymphocytes.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Navtemadlin treatment does not affect tumor infiltrating lymphocytes.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Navtemadlin treatment does not affect tumor infiltrating myeloid cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Navtemadlin treatment does not affect tumor infiltrating myeloid cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Crispr deletion of p53 in clone 8.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Crispr deletion of p53 in clone 8.